Angiomyolipoma medical therapy: Difference between revisions

Jump to navigation Jump to search
Faizan Sheraz (talk | contribs)
No edit summary
Faizan Sheraz (talk | contribs)
No edit summary
Line 5: Line 5:


==Overview==
==Overview==
There is no treatment for [[angiomyolipoma]]; the mainstay of therapy is embolisation or resection.
There is no treatment for [[angiomyolipoma]]; the mainstay of therapy is [[embolisation]] or resection.


==Treatment==
==Treatment==
Angiomyolipomas found incidentally usually require no therapy
There is no treatment for [[angiomyolipoma]]; the mainstay of therapy is [[embolisation]] or resection. Angiomyolipomas found incidentally usually require no therapy
Patients with kidney loss should be monitored for:
*Hypertension
*Nephrotoxic drugs such as:
**Certain pain relievers
**IV contrast agents


Patients with kidney loss should be monitored for hypertension (and treated for it if discovered) and avoid nephrotoxic drugs such as certain pain relievers and IV contrast agents. Such patients who are unable to communicate effectively (due to age or intellectual disability) are at risk of dehydration. Where multiple or large angiomyolipomas have caused [[chronic kidney disease]], dialysis is required.<ref name=Bissler2010>Bissler JJ, Henske EP. Renal Manifestations of Tuberous Sclerosis Complex. In: Kwiatkowski DJ, Wiittlemore DJ, Thiele EA, editors. Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics. Wiley-VCH Verlag GmbH; 2010. p. 321–325. ISBN 3-527-32201-9.</ref>
===[[Rapamycin]]===


[[Rapamycin]] and related drugs have been studied for their effect on angiomyolipomas due to their action on the pathways that are disrupted when TSC1 and TSC2 genes are broken. Small studies showed the lesions shrank but that the drugs were often toxic. The use of these drugs remains at the research stage.<ref name=Bissler2010>Bissler JJ, Henske EP. Renal Manifestations of Tuberous Sclerosis Complex. In: Kwiatkowski DJ, Wiittlemore DJ, Thiele EA, editors. Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics. Wiley-VCH Verlag GmbH; 2010. p. 321–325. ISBN 3-527-32201-9.</ref>
[[Rapamycin]] and related drugs have been studied for their effect on angiomyolipomas due to their action on the pathways that are disrupted when ''TSC1'' and ''TSC2'' genes are broken.<ref name=Bissler2010>Bissler JJ, Henske EP. Renal Manifestations of Tuberous Sclerosis Complex. In: Kwiatkowski DJ, Wiittlemore DJ, Thiele EA, editors. Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics. Wiley-VCH Verlag GmbH; 2010. p. 321–325. ISBN 3-527-32201-9.</ref>


==References==
==References==

Revision as of 19:22, 22 September 2015

Angiomyolipoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Angiomyolipoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Angiomyolipoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Angiomyolipoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Angiomyolipoma medical therapy

CDC on Angiomyolipoma medical therapy

Angiomyolipoma medical therapy in the news

Blogs on Angiomyolipoma medical therapy

Directions to Hospitals Treating Angiomyolipoma

Risk calculators and risk factors for Angiomyolipoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]

Overview

There is no treatment for angiomyolipoma; the mainstay of therapy is embolisation or resection.

Treatment

There is no treatment for angiomyolipoma; the mainstay of therapy is embolisation or resection. Angiomyolipomas found incidentally usually require no therapy Patients with kidney loss should be monitored for:

  • Hypertension
  • Nephrotoxic drugs such as:
    • Certain pain relievers
    • IV contrast agents

Rapamycin

Rapamycin and related drugs have been studied for their effect on angiomyolipomas due to their action on the pathways that are disrupted when TSC1 and TSC2 genes are broken.[1]

References

  1. Bissler JJ, Henske EP. Renal Manifestations of Tuberous Sclerosis Complex. In: Kwiatkowski DJ, Wiittlemore DJ, Thiele EA, editors. Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics. Wiley-VCH Verlag GmbH; 2010. p. 321–325. ISBN 3-527-32201-9.

Template:WikiDoc Sources